Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedExpanded the Study Details by adding a comprehensive list of enrollment sites across the United States and multiple countries and removed the HHS Vulnerability Disclosure section.SummaryDifference4%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision label in the page footer updated to v3.3.2; Revision v3.3.1 was removed.SummaryDifference0.0%

- Check45 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1; the visible study content appears unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check52 days agoChange DetectedAdded a new site in São Paulo, Brazil (01308-050) at Hospital Sirio Libanes (ID 261827) and removed the previous listing with the same ID. The government funding status notice was deleted from the page.SummaryDifference0.3%

- Check60 days agoChange DetectedAdded new locations such as Humanitas Istituto Clinico Catanese in Misterbianco (Italy) and Instituto de Oncología Angel H. Roffo in Buenos Aires, Argentina, and removed Memphis VA Medical Center and Osaka location entries; total locations increased from 307 to 309.SummaryDifference0.2%

- Check67 days agoChange DetectedNo changes to core study details (title, eligibility criteria, primary outcomes, enrollment, or locations) were observed; only minor layout and user interface adjustments were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.